메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Brii Biosciences Provides Corporate Updates and Reports 2025 Interim Financial Results

Multiple Ongoing Phase 2b Studies Advancing HBV Functional Cure Strategy Greater China Partnership with Joincare to Accelerate Development of Critical Care Antibiotic soralimixin Strong Cash Position to Pursue New Discovery Opportunities and Partnership Strategy Conference Calls Scheduled: English Session: August 21 at 9:00 p.m. HKT / 9:00 a.m. ET Chinese Session: August 22 at 9:00 a.m. HKT / August 21 at 9:00 p.m. ET DURHAM, N.C., and BEIJING, Aug. 21, 2025 -- Brii Biosciences Limited ("Brii Bio," or the "Company," stock code: 2137.HK),
- 김갑성 기자
- 2025-08-21 18:02
SINGZYME WINS 2025 AMGEN X NSG GOLDEN TICKET FOR BREAKTHROUGH BIOCONJUGATION PLATFORM

[ 메디채널 김갑성 기자 ] Now in its fourth year, the programme continues to empower biotech startups through ecosystem support and collaboration to advance science that serves patients. SINGAPORE, Aug. 21, 2025 -- Singzyme, a Singapore-based biotech startup pioneering next-generation bioconjugation solutions, has been named the winner of the 2025 Golden Ticket Programme in Singapore. The award is part of a joint programme by Amgen, a U.S.-based leader in biologic medicines and NSG BioLabs, Singapore's leading provider of biotechnology co-working laboratories and offices. Now in
- 김갑성 기자
- 2025-08-21 17:38
GC Biopharma's Study on Hunterase Lysosomal Delivery Mechanism Published in SCIE-Indexed Journal

YONGIN, South Korea, Aug. 21, 2025 -- GC Biopharma, a leading global pharmaceutical company based in South Korea, announced today that it has revealed the delivery mechanism of Hunterase (idursulfase beta), a recombinant enzyme replacement therapy for Hunter syndrome (MPS II). The research findings, detailing the role of N-glycosylation in lysosomal targeting, have been published in the International Journal of Biological Macromolecules, a prestigious SCIE-indexed journal. Hunter syndrome (MPS II) is a rare genetic disorder caused by mutations in the iduronate-2-s
- 김갑성 기자
- 2025-08-21 13:00
Debut of new form of health supplement product! WCC biomedical collaborate with Synmosa toward the niche market!

TAIPEI, Aug. 21, 2025 -- WCC Biomedical, a leader in novel drug delivery systems, will attend the upcoming NACDS Total Store Expo (TSE), where it will spotlight its proprietary WINMAP™ microarray patch (MAP) technology and launch two new products. To explore WINMAP™ technology for vaccines and pharmaceuticals, join WCC at the Total Store Expo on August 23–25 in San Diego, CA: Booth # 900 Following a successful debut at BIO Asia in Taiwan (July 23–27), WCC will offer demonstrations of its new products at TSE, allowing attendees to witness the benefits of microneedle-based
- 김갑성 기자
- 2025-08-21 09:23
바이탈 머티리얼즈, 양자 플럭스 광자 계수 CT(PCCT) 완전 수직 통합 기술 공개

[ 메디채널 김갑성 기자 ] 베이징 2025년 8월 21일 -- 8월 15일부터 17일까지 베이징에서 제31회 중국 국제 의료장비 전시회 및 과학 콘퍼런스(China-Hospeq 2025)가 개최됐다. 바이탈 머티리얼즈(Vital Materials)는 중국이 자체적으로 개발한 광자 계수 CT(PCCT) 스캐너 VITA Genesis를 공식 출시하며, 글로벌 의료 영상 기술이 '양자 플럭스(Quantum Flux)' 감지 시대에 진입했음을 알렸다. 이번 출시는 중국의 정밀 진단 및 치료 혁신에 힘을 실었다. PCCT의 핵심 기술인 광자 계수 검출기(PCD)는 기존 에너지 통합 검출기(EID)와 상당한 차이가 있다. 기존 CT 스캐너는 X선 광자를 먼저 가시광선으로 변환한 뒤, 다시 전기 신호로 바꾸는 과정을 거친다. 반면 PCCT 검출기는 반도체 소재를 활용해 X선 광자가 전자를 활성화해 에너지에 비례하는 전자-정공 쌍을 형성한다. 이렇게 발생한 전하 운반체는 전기장에 의해 분리돼 전기 펄스를 만들어낸다. ASIC(애플리케이션별 집적 회로)는 이 펄스를 에너지 구간별로 분류해 정밀한 광자 계수와 에너지 분해능을 제공한다. 이러한
- 김갑성 기자
- 2025-08-21 08:52
Telix 2025 Half-Year Results: Strong commercial performance enables investment for long-term growth

MELBOURNE, Australia and INDIANAPOLIS, Aug. 21, 2025 -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its financial results for the half-year ended 30 June 2025. All figures are in USD unless stated otherwise. H1 2025 key results[1] Group performance[2]: Reflects strategic investment for long-term value creation Revenue of $390.4 million, up by 63%[3] and on track to meet full year guidance[4]. Group gross profit margin of 53% reflects product mix change to include third-party RLS sales. Illuccix® m
- 김갑성 기자
- 2025-08-21 08:23
Angelalign Technology Denies Patent Infringement and Vows Vigorous Defense

SAN CLEMENTE, Calif., Aug. 21, 2025 -- Angelalign Technology Inc. (6699.HK) ("Angel") categorically denies accusations of patent infringement by Align Technology Inc. (ALGN) and promises a vigorous defense. "Angel has a rich heritage of clinically driven innovation during its 20-plus year history. Accusations by our competitor of patent violations are frivolous and entirely without merit," said Angel's Chief Commercial Officer and SVP, Rich Hirschland. "Angel has invested heavily in patent compliance since our founding. We are confide
- 김갑성 기자
- 2025-08-21 05:04
Sisram Medical Reports First-Half 2025 Results: Injectables Surge as AI-Powered EBD Strengthens Segment Positioning

HONG KONG, Aug. 20, 2025 -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; referred to collectively with its subsidiaries as the "Group"), a global consumer wellness group, featuring a distinguished synergistic ecosystem of business building blocks and consumer-focused approaches including Energy-Based Devices (EBD), and Injectables, alongside other complementary offerings, today announced its unaudited consolidated interim results for the six months ended June 30, 2025 (the "Reporting Period"). FINANCIAL HIGHLIGHTS Revenue was
- 김갑성 기자
- 2025-08-20 22:14
Zylox-Tonbridge Announces 2025 Interim Results: Strong Revenue Growth with Net Profit Surging Over 76% Year-over-Year

HANGZHOU, China, Aug. 20, 2025 -- Zylox-Tonbridge Medical Technology Co., Ltd. (HKEX: 2190, hereinafter referred to as "Zylox-Tonbridge" or the "Company") today announced its interim results for the six months ended June 30, 2025. The Company achieved robust revenue growth of 31.7% year-over-year (YoY) to RMB 482 million, while net profit surged by 76.0% to exceed RMB 121 million, representing a net profit margin of 25.1%. In the first half of 2025, Zylox-Tonbridge maintained solid performance in its core neurovascular and peripheral vascular intervention businesses
- 김갑성 기자
- 2025-08-20 21:41
Cell therapy is promising in treating psychiatric disorders, such as depression. -- A proof-of-principle study published in "Cell Stem Cell" by the laboratory of Dr. Chen, founder of UniXell Biotech, suggests this.

SHANGHAI, Aug. 20, 2025 -- On August 11, 2025, the research team led by Professor Yuejun Chen, founder of UniXell Biotech, published an article titled "Human stem cell-derived A10 dopaminergic neurons specifically integrate into mouse circuits and improve depression-like behaviors" in Cell Stem Cell, featured as a cover story. This study marks the first establishment of a technique to efficiently and directionally differentiate human pluripotent stem cells (hPSCs) into A10 subtype dopamine neurons. This breakthrough lays a critical scientific foundation for cell therapy of psychiatr
- 김갑성 기자
- 2025-08-20 20:49

이전

11 12 13 14 15 16 17 18 19 20

많이 본 기사

최근기사

2025-09-05_FRI

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 09월 05일 13시 00분